Drugs & Targets FDA issues revised draft guidance on charging for investigational drugs under an IND application September 09, 2022Vol.48 No.32
Drugs & Targets MD Anderson and Empyrean to codevelop novel radiation therapy technologies September 09, 2022Vol.48 No.32
Drugs & Targets MD Anderson and Erasca form R&D collaboration in RAS/MAPK-driven cancers September 09, 2022Vol.48 No.32
Drugs & TargetsFree Lynparza approved by the EC as adjuvant treatment for high-risk breast cancer August 05, 2022Vol.48 No.31
Drugs & TargetsFree MD Anderson and TransCode Therapeutics collaborate to advance RNA therapies August 05, 2022Vol.48 No.31
Drugs & TargetsFree Poseida, Roche to collaborate on allogeneic CAR T-cell therapies for hematologic malignancies August 05, 2022Vol.48 No.31
Drugs & Targets FDA accepts ImmunityBio’s BLA for bladder cancer therapy N-803 July 29, 2022Vol.48 No.30
Drugs & Targets Merck pays $35M to Kelun-Biotech for rights to investigational antibody drug conjugate July 29, 2022Vol.48 No.30
Drugs & Targets Mission Bio establishes early access program for single-cell measurable residual disease detection in blood cancers July 29, 2022Vol.48 No.30
Drugs & Targets FDA grants eltanexor with fast track designation; EU Commission designates eltanexor as an orphan medicinal product July 22, 2022Vol.48 No.29
